z-logo
HomeZAIABlog
open-access-imgOpen Access
Dupilumab
Author(s) -
E. Gysling N. Marty N. Marty
Publication year - 2020
Publication title -
pharma-kritik
Language(s) - German
Resource type - Journals
SCImago Journal Rank - 0.101
H-Index - 2
ISSN - 1010-5409
DOI - 10.37667/pk.2019.1082
Subject(s) - dupilumab , medicine , atopic dermatitis , dermatology
Ein neues Biologikum, das zur systemischen Behandlung der atopischen Dermatitis eingesetzt werden kann. Dupilumab ist bisher nicht direkt mit anderen systemischen Therapien verglichen worden und verursacht sehr häufig Augensymptome (insbesondere Konjunktivitis und Keratitis).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

AboutCareersPublisher PartnersContact UsGet Organisational Trial or Quote

Learn

FAQsBlogTerms of UsePrivacy Policy

Download the Zendy App

Get it on
Google Play
Download on the
App Store

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.